Edesa Biotech
EDSA
22 hedge funds and large institutions have $5.51M invested in Edesa Biotech in 2022 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 4 closing their positions.
171% more capital invested
Capital invested by funds: $2.03M → $5.51M (+$3.47M)
133% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 3
1.48% more ownership
Funds ownership: 0.38% → 1.86% (+1.5%)
12% less funds holding
Funds holding: 25 → 22 (-3)
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$5.76M |
| 2 |
Renaissance Technologies
New York
|
+$197K |
| 3 |
National Bank of Canada
Montreal,
Quebec, Canada
|
+$37.1K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$11.9K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$11.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$85K |
| 2 |
VF
Virtu Financial
New York
|
-$84K |
| 3 |
Two Sigma Investments
New York
|
-$5.96K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$2K |
| 5 |
Morgan Stanley
New York
|
-$1.08K |
EDSA Hedge Fund Activity: Q1 2022 in Review
22 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Edesa Biotech (EDSA) for Q1 2022, worth a combined $5.51M — up 171% from $2.03M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of EDSA and 1 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 7 added.
The largest buyer was Armistice Capital, opening a new position worth an estimated $5.76M. The largest seller was Citadel Advisors, exiting entirely with an estimated $85K sold.
- 22 institutional investors held Edesa Biotech (EDSA) as of Q1 2022, down from 25 in Q4 2021.
- Funds reported $5.51M of Edesa Biotech stock for Q1 2022, up 171% quarter-over-quarter.
- 1 fund opened new Edesa Biotech positions in Q1 2022 and 4 closed out, a net change of -3 holders.
- The largest Edesa Biotech buyer in Q1 2022 was Armistice Capital, an estimated $5.76M added.
- The largest Edesa Biotech seller in Q1 2022 was Citadel Advisors, an estimated $85K sold.
Based on aggregated 13F filings for Q1 2022.